PREMIUM
2026
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction (PREMIUM)
In 2,216 patients with STEMI undergoing primary PCI, aspirin-free prasugrel monotherapy was not non-inferior to 12 months of dual antiplatelet therapy for death, myocardial infarction or stroke at 12 months.
Result
Efficacy: Composite of all-cause death, myocardial infarction or stroke at 12 months (non-inferiority)HR 1.34 (95% CI 1.02-1.75) · P = 0.40
Safety: Major bleedingHR 0.66 (95% CI 0.47-0.91)
Below 1 favours aspirin-free prasugrel monotherapy, above 1 favours 12 months of dual antiplatelet therapy.
Event rates Aspirin-free prasugrel monotherapy 11.0% vs 12 months of dual antiplatelet therapy 8.5% (composite of all-cause death, myocardial infarction or stroke at 12 months (non-inferiority))
Also reported: Non-inferiority not met. Definite or probable stent thrombosis and serious adverse events were similar.
- Subtopic
- Aspirin-free antiplatelet strategy
- Design
- Investigator-initiated, multicentre, open-label randomised controlled trial in Japan; 1:1 randomisation before primary PCI; all patients receive platinum-chromium everolimus-eluting stents (SYNERGY) with routine intravascular imaging guidance; non-inferiority design for the primary endpoint; 12-month follow-up
- Relevance
- Important: one of several pillars.
- Source
- Takahashi K, Kozuma K, Morino Y, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2606997
Discussion & critique
Dropping aspirin from the start of primary PCI failed its non-inferiority test, and the confidence interval sits entirely above 1: 2.5 percentage points more death, stroke or infarction, bought for 2.8 points less major bleeding. That is a trade, not a free lunch, and the trial was not designed to say which side a given patient should take. Japanese, open-label, and run with the low prasugrel dose used in Japan rather than the Western regimen, so the ischaemic arm of the trade may not transfer directly.